Treatment of choice for T2 carcinoma of nasopharynx is –
**Core Concept**
The treatment of nasopharyngeal carcinoma, particularly T2 stage, involves a multidisciplinary approach combining radiation therapy, chemotherapy, and surgery to optimize outcomes. The primary goal is to achieve local control and prevent distant metastasis.
**Why the Correct Answer is Right**
The treatment of choice for T2 carcinoma of the nasopharynx is intensity-modulated radiation therapy (IMRT) combined with concurrent chemotherapy. IMRT allows for precise targeting of the tumor, minimizing damage to surrounding critical structures such as the eyes, optic nerves, and brainstem. Concurrent chemotherapy, typically with cisplatin, enhances the effectiveness of radiation therapy and improves survival rates. The combination of IMRT and chemotherapy is supported by evidence from clinical trials and is considered the standard of care for locally advanced nasopharyngeal carcinoma.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because surgery alone is not sufficient for treating T2 nasopharyngeal carcinoma, as it may not address potential microscopic disease or prevent recurrence.
**Option B:** This option is incorrect because chemotherapy alone, without radiation therapy, is not adequate for treating T2 nasopharyngeal carcinoma, which requires a combined modality approach.
**Option C:** This option is incorrect because external beam radiation therapy (EBRT) alone may not provide sufficient dose escalation to the tumor, particularly for T2 lesions, and may increase the risk of toxicity.
**Clinical Pearl / High-Yield Fact**
The use of IMRT with concurrent chemotherapy has significantly improved outcomes for patients with nasopharyngeal carcinoma, with improved local control and survival rates compared to conventional radiation therapy.
**Correct Answer:** C. IMRT with concurrent chemotherapy